10^th International Tissue Repair and Regeneration Congress June 13-14, 2019 Scandic Jarvenpaa | Helsinki, Finland

Deven Patel, the CEO, President and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A. GIOSTAR was formed with the vision to provide affordable stem cell based therapies to the masses around the world suffering from degenerative or genetic diseases and unable to afford today’s high cost of the treatment. He was honored with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world. He was also bestowed upon Asian Heritage Award for his business leadership in the field of stem cell science. GIOSTAR under the leadership of Mr. Patel is in charge of developing stem cell transplant program for four different State Governments in India with total population of approx. 155 million. GIOSTAR, in collaborations with Government of Gujarat, India, world's largest state of the art Stem Cell Treatment Hospital in India. GIOSTAR is in process of developing its facility in China, Thailand, Colombia, Bahamas, Dubai and Austalia.

The Stem Cell Therapy and Its Emerging Markets

Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine worked at the Royal Free Hospital and University College London for over 26 years, during this time he spent a period of time at Harvard Medical School looking at caused of cardiovascular diseases and a year at Johns Hopkins Medical School looking at treatment of liver. He published more than 647 peer-reviewed research papers, and registered 14 UK and International patents. He is currently CEO of NanoRegMed Ltd, working on the commercialisation of his research. During his career Prof Seifalian has led and managed many large projects with successful outcomes in terms of commercialisation and translation to patients. In 2007 he was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants by Medical Future Innovation, and in 2009 he received a Business Innovation Award from UK Trade & Investment (UKTI). He was the European Life Science Awards’ Winner of Most Innovative New Product 2012 for the “synthetic trachea”. Prof Seifalian won the Nanosmat Prize in 2013 and in 2016 he received the Distinguish Research Award in recognition of his outstanding work in regenerative medicine from Heals Healthy Life Extension Society. His achievements include development of the world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials, bioactive molecules and stem cell technology.

Nanotechnology & Regenerative Medicine

Mauro Alini graduated in Chemistry from the University of Lausanne (Switzerland) in 1983. Since then he has been involved in connective tissue research, starting from his Ph.D. research work, which focused on the isolation and characterization of proteoglycans extracted from both normal human mammary gland and carcinomas thereof. In September 1988, he joined the Joint Diseases Laboratory (under Dr. A. R. Poole’s direction) at the Shriners Hospital in Montreal to work on quantitative and qualitative changes in extracellular matrix proteins (particularly proteoglycans and collagens) of the growth plate tissue before and at the time of cartilage matrix calcification during endochondral bone formation. In January 1995, he was appointed as an Assistant Professor at the Division of Orthopaedic Surgery of the McGill University (Chair Prof. M. Aebi) and head of the Biochemistry Unit of the Orthopaedic Research Laboratory, working to develop new biological approaches to treating intervertebral disc damage. Since July 2000, he is in charge of the Musculoskeletal Regeneration Program (40 scientists) at the AO Research Institute (Davos, Switzerland), focusing on cartilage, bone and intervertebral disc tissue engineering. Since September 2009 is also Vice-Director of the same Research Institute. He received the Marshall R. Urist Award in 2015 from the Orthopaedic Research Society (USA).

Cartilage, bone and intervertebral disc tissue engineering

Roberta Di Pietro got the degree in Medicine cum Laude in 1985 and the Master in Sports Medicine cum Laude in 1988, University of Chieti, Italy. She worked as a visiting scientist in UK at the Biochemistry Department, AFRC, Cambridge; in USA at the Pathology Department, USUHS, Bethesda, and at the Institute of Human Virology, University of Maryland, Baltimore. Since 2005 she has worked at the G. d’Annunzio University of Chieti, Italy, as a Full Professor of Histology. She is Executive Guest Editor of Current Pharmaceutical Design, Member of the Editorial Board of Horizon Research Publishing Corporation, USA, Review Editor and Guest Editor for Frontiers in Oncology, and Honorary Member of the Editorial Board of the International Journal of Oncology. In 2010 she was recognized as a Registered Referee for Archives of Ophthalmological Reviews and Reproductive Biology and Endocrinology and since 2016 for Spandidos Publications. She is now author of 194 scientific publications plus international e-book and Italian textbook chapters.

Histology ,electron microscopy, signal transduction, amniotic membrane.

Dr Kellner is now founder and chief scientist of Mesencell Biotech, which focuses on autologous stem cell and dendritic cell treatments in the Middle East and Northern Africa, co-founder and chief scientist of Med Cell Bahamas with a government licence for stem cell treatments in the Bahamas, co-founder and chief scientist of Med Cell International in the USA and co-founder, board member and chief scientist of Med Cell plc responsible for worldwide research projects and clinical trials for diseases such as Alzheimer Disease, Parkinson Disease, Diabetes T1 and T2 and osteoarthritis. Apart from his main research focus into neurological disease (Alzheimer and Parkinson Disease and retinal disease) Dr Kellner mentors young biotech start-up companies and actively seeks and finds collaboration with other research institutes and local governments. Dr Kellner is also Editor in Chief of Journal of Stem Cell Research & Therapeutics and the Journal of Advance Research on Alzheimers & Parkinsons Disease (ARAP) and Editor of Archives in Neurology & Neuroscience.

Mesenchymal Stem Cells, Dendritic Cells, Biomarkers

Dr.Omid Panahi , Graduated from Centro Escolar University on 2013 in field of Doctor of Dental Mediciene( DMD), and MSc Oral and maxillofacial surgery at yeditepe university, Istanbul, turkey. He has published more than 40 papers in reputed journals and has been serving as an editorial board member of isi journals.

Stem cell therapy, tissue bioengineering, implant dentistry, Regenerative dentistry

MD degrees at Westhill University and the National Autonomous University of Mexico and he qualified Physician Surgeon. Diplomate in Aesthetic Medicine from the Autonomous University of Guadalajara, and He is an Advanced Fellow with the American Board of Anti-Ageing and Regenerative Medicine, a Visiting Scholar in Dermatology at the University of North Carolina, Chapel Hill. Fellow in Stem Cell Medicine with both the American Academy of Anti-Aging Medicine and University of South Florida.

First contact patient care Integrated Medicine Approach Stem cells Medical Application (mesenchymal stem cells from Adipose tissue, Bone Marrow and Human Placenta derivate) PRP Preparation and Application (face, neck, hands, chest, abdominal area, gluteal area, etc.) Minimal Invasive Liposculpture (Abdominal area, back, arms); Botox Medical applications Minor and major surgical procedures Major surgical procedures assistant (Cosmetic, orthopaedic, abdominal surgeries) Mesotherapy Expert Bioidentical Hormone Replacement Therapy (BHRT) Medical Application Weight Control Expert

Kristine Freude is an Associate Professor at the University in Copenhagen and Director of the Center for Excellence in Neuroscience "BrainStem". Previously she has been at the University of California at Irvine, where she received her training in Stem Cell Biology funded by the California Institute for Regenerative Medicine (CIRM). Her current research is focused on disease modeling using induced pluripotent stem cells (iPSC) from patients with neurodegenerative diseases such as Alzheimer's as well as CRISPR-Cas9 gene edited iPSCs carrying mutations associated with neurodegenerative diseases. Her research is funded by Innovation Foundation Denmark, Novo Nordisk Foundation and the Danish Alzheimer's Foundation.

Induced pluripotent stem cells, Neurodegenerative diseases